Business Wire

ZIVO Reports Favorable Results from 42-Day Confirmatory Study of its Coccidiosis Treatment in Broiler Chickens

BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--ZIVO Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates ...
Business Wire

Trial Results Confirm Efficacy of ZIVO Bioscience’s Non-Antibiotic Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler Chickens

BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional ...
The Daily Journal

ToltraMax: A New Standard in Coccidiosis Treatment and Accessible Pet Care

When it comes to animal health, few challenges are as pervasive and potentially devastating as coccidiosis—a parasitic disease caused by protozoa of the genus Eimeria. Affecting a wide range of ...
Nasdaq

ZIVO Reports Negative Results Of Study With Product Candidate For Coccidiosis Treatment In Chickens

(RTTNews) - Zivo Bioscience Inc. (ZIVO) announced negative results of a four-month study performed by a third party on behalf of a potential partner company, which included a 42-day coccidiosis trial ...
Nasdaq

Major Global Animal Health Company Launches 42-Day Confirmatory Study with ZIVO Bioscience’s Coccidiosis Treatment in Broiler Chickens

BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)-- ZIVO Bioscience, Inc. (NASDAQ: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product ...